Compare KeyCorp (KEY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Mesoblast Limited — how do they compare? KeyCorp trades at $22.95 (market cap $24.32B), while Mesoblast Limited trades at $16.8 (market cap $2.21B). The key difference: KeyCorp is far larger — about 11× Mesoblast Limited's market cap, and KeyCorp pays a 3.61% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KEY | MESO | |
|---|---|---|
Market Cap | $24.32B | $2.21B |
Sector | Financials | Technology |
52-Week High | $23.99 | $20.96 |
52-Week Low | $16.78 | $12.88 |
Dividend Yield | 3.61% | — |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.855, up 0.77% for the day, with a P/E of 13.27 and P/B of 1.41. Recent quarterly earnings have consistently beaten estimates, with Q2 2026 EPS of $0.44 versus $0.42 expected. Technical indicators show a bearish trend, but fundamentals are supported by strong net interest income growth and strategic acquisitions like Clearwater UK.
The outlook is positive with a consensus price target of $29.41, implying 29% upside. Risks include economic uncertainty impacting loan growth and margin pressure from rising expenses. Analyst sentiment is bullish with 61% buy ratings, but investors should monitor execution of fee-based growth initiatives.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
